# Shanghai Bailong Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shanghai-bailong-biotechnology-co

- Industry: Biotechnology
- Headquarters: Shanghai, China
- Website: www.apeiron-bio.com
- Total disclosed funding: $2.8M
- Latest round: Series A (Mar 29, 2022)
- Investors on record: 2

## About

Based in Shanghai, China and founded in 2019, Shanghai Bailong Biotechnology Co., Ltd. operates as a genetic artificial intelligence technology for innovative drug development, dedicated to artificial intelligence and novel biotechnology-led innovative drug development. The company also established a branch officer in San Francisco Bay Area.

The Company has established a unique pipeline of precision oncology therapies in the area of CDKs and synthetic tumor lethality. The company and its strategic partner Exscientia are developing a series of innovative CDK therapies. The company also has cooperation with WuXi AppTec and Pharmaron and other enterprises.

The company will accelerate CDK7 inhibitor program into clinical trials. The company will also continue to integrate artificial intelligence and structural biology technologies to enhance the company's drug discovery platform.

## Funding rounds

- Series A, Mar 29, 2022, $2.8M — Panacea Venture, Viva Ventures Biotech

## Investors

- Panacea Venture (https://capitalatlas.ai/funds/panacea-venture) — Series A
- Viva Ventures Biotech (https://capitalatlas.ai/funds/viva-ventures-biotech) — Series A